DexCom stock jumps in premarket after early Q4 sales and 2026 outlook; what DXCM investors watch next
DexCom shares rose about 5% premarket Tuesday after the company reported preliminary Q4 revenue of $1.26 billion, up 13% year over year, and issued 2026 guidance above prior expectations. U.S. sales reached $892 million, with international revenue at $368 million. The company reaffirmed 2025 margin targets and raised 2026 goals. Barclays downgraded DexCom, citing competitive pressures despite strong sales.